Tesamorelin is a synthetic 44-amino acid polypeptide corresponding to native human GHRH(1-44) with a critical N-terminal trans-3-hexenoic acid modification. This structural change confers resistance to DPP-IV enzymatic cleavage — the primary degradation pathway of native GHRH — extending biological half-life from minutes to approximately 26–38 minutes. The peptide is supplied as a lyophilized powder for in vitro research and is intended strictly for qualified researchers conducting laboratory investigations of GHRH receptor pharmacology, GH axis biology, and related research domains. Each lot ships with a Certificate of Analysis documenting ≥98% purity by HPLC.
Tesamorelin binds selectively to GHRH receptors (GHRH-R) on anterior pituitary somatotroph cells, activating the Gs-cAMP-PKA-CREB signaling cascade to drive GH gene transcription and pulsatile GH release. Unlike exogenous GH administration, this mechanism preserves normal IGF-1 feedback regulation, maintaining physiological GH pulsatility rather than producing sustained supraphysiological GH elevation. With over 150 PubMed-indexed publications, tesamorelin has been characterized extensively in clinical research for HIV-associated lipodystrophy, hepatic lipid biology, metabolic dysfunction research, and neurocognitive investigations.
Tesamorelin (Egrifta) was first authorized in 2010 for HIV-associated lipodystrophy; the improved F8 formulation (Egrifta WR) was authorized in March 2025 with updated reconstitution protocol and reduced injection volume, maintaining bioequivalence.
Research Use Only. Supplied for in vitro laboratory investigation by qualified researchers. Not for human or veterinary consumption, diagnosis, treatment, prevention, or cure of any condition.
